Telemetrically monitored arrhythmogenic effects of doxorubicin in a dog model of heart failure

Vaynblat, Mikhail; Pagala, Murali; Davis, Wellington J.; Bhaskaran, Dinesh; Fazylov, Rafael; Gelbstein, Chaya; Greengart, Alvin; Cunningham, Joseph N.

doi:10.1016/s0928-4680(03)00026-9

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been observed in dogs receiving doxorubicin and is rarely associated with clinical signs 19 . There have been reports of sudden death attributed to doxorubicin‐induced arrhythmia in people and in experimental models in dogs, although this has not been observed in dogs or to our knowledge in people receiving epirubicin 20,21 . In this study only one dog developed a possible acute cardiotoxicity arrhythmia.…”

Section: Discussionmentioning

confidence: 53%

Toxicity associated with epirubicin treatments in a large case series of dogs

Marrington

Killick

Grant

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

Epirubicin is a stereoisomer of doxorubicin that is widely used in human oncology. The purpose of this study was to evaluate the toxicity associated with epirubicin administration in dogs. Three hundred and fifteen treatments were administered to 139 dogs. Patients received between one and seven doses. One hundred and sixteen treatments were associated with toxicity in 81 patients (50 episodes of lethargy, 49 of diarrhoea, 42 of vomiting, 40 of anorexia, 2 hypersensitivity reactions and 2 suspected extravasations). Thirty-six (11%) adverse events resulted in hospitalization in 33 (24%) patients, of which 15 were neutropenic and 9 pyrexic. Mean duration of hospitalization was 3.4 days and 33 patients recovered uneventfully. Owners of 11 patients declined further treatment after toxicity occurred. After 25 treatments associated with toxicity, dose reductions reduced toxicity. The use of prophylactic anti-emetics, gastroprotectants and antibiotics did not reduce the frequency of gastrointestinal toxicity.

show abstract

Section: Discussionmentioning

confidence: 53%

Toxicity associated with epirubicin treatments in a large case series of dogs

Marrington

Killick

Grant

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“… This has not been reported in dogs (including the dogs in this study) or to our knowledge in people receiving epirubicin. However, only two dogs in this study had a record of ECG monitoring during or after infusion, although patients pulse characteristics were monitored during infusion and auscultation was carried out intermittently.…”

Section: Discussionmentioning

confidence: 99%

Epirubicin as part of a multi‐agent chemotherapy protocol for canine lymphoma

Elliott

Cripps

Marrington

et al. 2012

Vet Comparative Oncology

View full text Add to dashboard Cite

The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T-cell lymphoma and those classified as WHO substage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin-containing protocols. Epirubicin as part of a multi-agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin-containing protocols.

show abstract

“…As for the electrophysiological performance, the beating rate and beat-to-beat variation (SDISI) changed dose-dependently. The doxorubicin-induced arrhythmia was found both in vivo and in vitro detection; its mechanism was unclear but might be related with modification of sarcolemmal Ca 2+ transport, attenuation in adenylate cyclase and so forth (Vaynblat et al, 2003). In addition, Ca 2+ overload caused by larger trans-sarcolemmal Ca 2+ influx and Ca 2+ release from the sarcoplasmic reticulum was another pathway of cardiotoxicity (Torii et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

“…Pein et al (2004) studied the cardiac function status in children after doxorubicin therapy by cardiac Doppler Ultrasonography and Electrocardiogram (ECG), and found that 39% of the children had severe cardiac dysfunction or major ventricular overload conditions in average follow-up of 18 years. Moreover, acute damage would cause sudden death due to the induced fatal arrhythmias (Vaynblat et al, 2003). Different from the clinical studies, histology is commonly used to study cardiotoxicity in cellular and molecular levels.…”

Section: Introductionmentioning

confidence: 99%